Marcelo H. Losso

Hospital General De Agudos Dr. José María Ramos Mejía
Ramos Mejia, B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Barriers to timely HIV diagnosis in the rapid testing era

Barriers to timely HIV diagnosis in the rapid testing era

Journal: Medicina

Published: August 16, 2026

Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.

Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.

Journal: Lancet (London, England)

Published: January 22, 2026

Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial.

Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 21, 2026

Chemsex Practice Among PrEP Users in Buenos Aires, Argentina.

Chemsex Practice Among PrEP Users in Buenos Aires, Argentina.

Journal: AIDS and behavior

Published: January 08, 2026

Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial.

Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: September 22, 2025

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk.

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk.

Journal: Trials

Published: September 18, 2025

A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study.

A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 01, 2025

Implementation of an Online Drug-Drug Interaction Screener for the STRIVE Ensitrelvir Trial for COVID-19.

Implementation of an Online Drug-Drug Interaction Screener for the STRIVE Ensitrelvir Trial for COVID-19.

Journal: Open forum infectious diseases

Published: March 10, 2025

Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.

Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.

Journal: Communications medicine

Published: February 14, 2025

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.

Journal: The New England journal of medicine

Published: November 27, 2024

Investigating the Impact of Host Genetics on the Risk of Disease Progression in Individuals With Influenza.

Investigating the Impact of Host Genetics on the Risk of Disease Progression in Individuals With Influenza.

Journal: Immunity, inflammation and disease

Published: July 18, 2024

Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.

Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.

Journal: iScience

Published: June 28, 2024

Showing 1-12 of 75

Last Updated: 09/26/2026